Johnson & Johnson vs AbbVie Inc.
A head-to-head of Johnson & Johnson (JNJ) and AbbVie Inc. (ABBV) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | JNJ | ABBV |
|---|---|---|
| Market Cap | $555.94B | $355.43B |
| P/E (TTM) | 25.81 | 106.96 |
| Forward P/E | 17.72 | 13.41 |
| P/S | 5.77 | 5.66 |
| P/B | 8.58 | -57.26 |
| EV/EBITDA | 17.48 | 24.76 |
| Dividend Yield | 1.80% | 2.95% |
| Profit Margin | 21.83% | 5.79% |
| Gross Margin | 67.88% | 70.24% |
| Operating Margin | 27.17% | 32.85% |
| Revenue Growth (YoY) | +9.91% | +12.43% |
| FCF Yield | 3.13% | 5.62% |
| Debt / Equity | 67.73 | — |
| Current Ratio | 1.03 | 0.80 |
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.